Rivaroxaban inhibits angiotensin II-Induced activation in cultured mouse cardiac fibroblasts through the modulation of NF-κB Pathway

International Heart Journal

Volumn 56, Issue 5, 2015, Pages 544-550

  Hashikata, Takehiro ^a   Yamaoka Tojo, Minako ^a,b   Namba, Sayaka ^a   Kitasato, Lisa ^a   Kameda, Ryo ^c   Murakami, Masami ^c   Niwano, Hiroe ^d   Shimohama, Takao ^c   Tojo, Taiki ^c   Ako, Junya ^a,c  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TAMAGAWA UNIVERSITY   (Japan)

Author keywords

Anticoagulant; Cardiac fibrosis; Cell signaling; Factor Xa inhibitor; Inflammation

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; ANGIOTENSIN II; COLONY STIMULATING FACTOR 1; INTERLEUKIN 16; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 5; RIVAROXABAN; STROMAL CELL DERIVED FACTOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; BLOOD CLOTTING FACTOR 10A INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEINASE ACTIVATED RECEPTOR 2;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; DRUG EFFECTS; FIBROBLAST; FIBROSIS; HEART MUSCLE; METABOLISM;

ANGIOTENSIN II; ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FACTOR XA INHIBITORS; FIBROBLASTS; FIBROSIS; MICE; MYOCARDIUM; NF-KAPPA B; RECEPTOR, PAR-2; RIVAROXABAN; SIGNAL TRANSDUCTION;

EID: 84942940008     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.15-112     Document Type: Article

References (45)

1. Quercioli A, Mach F, Montecucco F. Novel treatment strategy with direct renin inhibition against heart failure. Panminerva Med 2010; 52: 41-51. (Review)
2. Chen W, Frangogiannis NG. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev 2010; 15: 415-22. (Review)
3. Shyu KG, Wang BW, Chen WJ, Kuan P, Hung CR. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 2010; 12: 219-26.
4. Fukui M, Goda A, Komamura K, et al. Changes in collagen metabolism account for ventricular functional recovery following beta- blocker therapy in patients with chronic heart failure. Heart Vessels (in press)
5. Olson ER, Shamhart PE, Naugle JE, Meszaros JG. Angiotensin IIinduced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase Cdelta and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 2008; 51: 704-11.
6. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification: basic science to clinical practice. Heart 2009; 95: 616-23. (Review)
7. Simionescu A, Simionescu DT, Vyavahare NR. Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: role of myofibroblasts in vascular calcification. Am J Pathol 2007; 171: 116-23.
8. Jiang B, Xu S, Hou X, Pimentel DR, Cohen RA. Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK. J Biol Chem 2004; 279: 20363-8.
9. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34. (Review)
10. Hara M, Sakata Y, Nakatani D, et al. Renin-angiotensin-aldosterone system polymorphisms and 5-year mortality in survivors of acute myocardial infarction: a report from the Osaka Acute Coronary Insufficiency Study. Int Heart J 2014; 55: 190-6.
11. Fujita S, Shimojo N, Terasaki F, et al. Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels 2013; 28: 646-57.
12. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999; 100: 999-1008. (Review)
13. Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor- 2 activation. Am J Pathol 2008; 172: 309-20.
14. Kitasato L, Yamaoka-Tojo M, Hashikata T, et al. Factor Xa in mouse fibroblasts may induce fibrosis more than thrombin. Int Heart J 2014; 55: 357-61.
15. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
16. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
17. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
18. Harada M, Itoh H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997; 96: 3737-44.
19. Hulkower KI, Herber RL. Cell migration and invasion assays as tools for drug discovery. Pharmaceutics 2011; 3: 107-24.
20. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation. Circ Res 2004; 95: 276-83.
21. Zhao W, Su W, Kuang P, et al. The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int J Oncol 2012; 41: 457-64.
22. McNabb DS, Reed R, Marciniak RA. Dual luciferase assay system for rapid assessment of gene expression in Saccharomyces cerevisiae. Eukaryot Cell 2005; 4: 1539-49.
23. Xu R, Lin F, Zhang S, Chen X, Hu S, Zheng Z. Signal pathways involved in reverse remodeling of the hypertrophic rat heart after pressure unloading. Int J Cardiol 2010; 143: 414-23.
24. Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014; 35: 242-9.
25. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
26. Zhou Q, Bea F, Preusch M, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011: 2011; 432080.
27. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
28. Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88: 947-53.
29. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-8.
30. Camerer E, Trejo J. Cryptic messages: is noncoagulant tissue factor reserved for cell signaling? Proc Natl Acad Sci U S A 2006; 103: 14259-60.
31. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008; 14: 429-40. (Review)
32. Khokha R, Waterhouse P. The role of tissue inhibitor of metalloproteinase- 1 in specific aspects of cancer progression and reproduction. J Neurooncol 1994; 18: 123-7. (Review)
33. Berry MF, Woo YJ, Pirolli TJ, et al. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Heart Lung Transplant 2004; 23: 1061-8.
34. Lovelock JD, Baker AH, Gao F, et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibrob lasts. Am J Physiol Heart Circ Physiol 2005; 288: H461-8.
35. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005; 65: 40-51. (Review)
36. del Zoppo GJ, Milner R, Mabuchi T, et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007; 38: 646-51. (Review)
37. Reunanen N, Li SP, Ahonen M, Foschi M, Han J, Kähäri VM. Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 2002; 277: 32360-8.
38. Keates AC, Castagliuolo I, Cruickshank WW, et al. Interleukin 16 is up-regulated in Crohn’s disease and participates in TNBS colitis in mice. Gastroenterology 2000; 119: 972-82.
39. Skundric DS, Cai J, Cruikshank WW, Gveric D. Production of IL- 16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation 2006; 3: 13.
40. Hessel EM, Cruikshank WW, Van Ark I, et al. Involvement of IL- 16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol 1998; 160: 2998-3005.
41. Mathy NL, Bannert N, Norley SG, Kurth R. Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol 2000; 164: 4429-32.
42. Tamaki S, Mano T, Sakata Y, et al. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. PLoS One 2013; 8: e68893.
43. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res 2012; 110: 126-44. (Review)
44. Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 2014; 35: 233-41.
45. van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013; 6: 740-7.